This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • The emergence of clinical resistance to tigecyclin...

The emergence of clinical resistance to tigecycline

Read time: 1 mins
Published:25th Mar 2020
Tigecycline (TIG) exhibits broad-spectrum activity against many Gram-positive and Gram-negative pathogens. However, clinical resistance has emerged recently and has been detected following treatment with TIG. This observation suggests that long-term monotherapy may carry a high risk for TIG resistance. TIG resistance is observed most frequently inAcinetobacter baumannii�and Enterobacteriaceae, especially in multidrug-resistant strains. Resistance�nodulation�cell division (RND)-type transporters and other efflux pumps may be factors for decreased sensitivity to TIG. Therefore, TIG should be cautiously used in the clinic, and efflux-mediated resistance should be closely monitored in order to prolong the lifespan of this useful antibiotic.

Read abstract on library site